This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cadence Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Cadence Pharmaceuticals, Inc. (CADX)

Q1 2010 Earnings Call Transcript

May 6, 2010 4:30 pm ET

Executives

Bill LaRue – SVP, CFO, Treasurer and Assistant Secretary

Ted Schroeder – President and CEO

Analysts

Eric Schmidt – Cowen and Company

Gary Nachman – Leerink Swan

John Newman – Oppenheimer

Greg Beicher [ph] – Banc of America/Merrill Lynch

Presentation

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Cadence Pharmaceuticals first quarter 2010 financial results conference call. On the call today is Ted Schroeder, President and CEO; Jim Breitmeyer, Executive Vice President and Chief Medical Officer; and Bill LaRue, Senior Vice President and Chief Financial Officer. At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for questions and answers after the management presentation. (Operator Instructions)

Our first speaker today is Bill LaRue. Go ahead, sir.

Bill LaRue

Thank you. Good afternoon, everyone. Before we get started today, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward looking statements regarding

our belief that our third party manufacturer will time we resolve FDA's observations with respect to the OFIRMEV manufacturing facility, the timeline from potential for approval of the NDA for OFIRMEV, and our belief that our current cash resources will be sufficient to fund our operations through the approval of the NDA.

All such forward looking statements are based on our current beliefs and expectations, and should not be regarded as a representation that any of our plans will be achieved. Actual results may differ materially from those discussed during this conference call due to the risks and uncertainties inherent in our business, which include

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
AAPL $132.04 1.87%
FB $80.55 1.50%
GOOG $539.80 1.40%
TSLA $247.43 -0.01%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs